Brian M. Culley Acquires 40,000 Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Stock

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) CEO Brian M. Culley purchased 40,000 shares of the company’s stock in a transaction on Thursday, November 21st. The stock was purchased at an average price of $0.60 per share, with a total value of $24,000.00. Following the completion of the transaction, the chief executive officer now owns 194,842 shares of the company’s stock, valued at approximately $116,905.20. This trade represents a 25.83 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Lineage Cell Therapeutics Stock Down 16.0 %

LCTX stock opened at $0.50 on Friday. Lineage Cell Therapeutics, Inc. has a 1-year low of $0.50 and a 1-year high of $1.61. The company has a market capitalization of $95.16 million, a price-to-earnings ratio of -4.20 and a beta of 1.28.

Analysts Set New Price Targets

Separately, Craig Hallum assumed coverage on shares of Lineage Cell Therapeutics in a report on Tuesday, August 20th. They issued a “buy” rating and a $4.00 target price for the company.

Hedge Funds Weigh In On Lineage Cell Therapeutics

Several hedge funds have recently modified their holdings of LCTX. Price T Rowe Associates Inc. MD lifted its position in shares of Lineage Cell Therapeutics by 77.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 161,314 shares of the company’s stock worth $239,000 after buying an additional 70,418 shares in the last quarter. Comerica Bank raised its holdings in shares of Lineage Cell Therapeutics by 84,745.8% during the 1st quarter. Comerica Bank now owns 250,295 shares of the company’s stock worth $370,000 after acquiring an additional 250,000 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Lineage Cell Therapeutics by 35.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 435,958 shares of the company’s stock valued at $435,000 after acquiring an additional 114,762 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of Lineage Cell Therapeutics by 15.1% in the second quarter. Rhumbline Advisers now owns 132,491 shares of the company’s stock valued at $132,000 after purchasing an additional 17,411 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in Lineage Cell Therapeutics by 10.0% in the second quarter. Renaissance Technologies LLC now owns 583,622 shares of the company’s stock worth $582,000 after purchasing an additional 53,022 shares during the last quarter. Hedge funds and other institutional investors own 62.47% of the company’s stock.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.